Disease · HP_0000093
Proteinuria
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Proteinuria. Diseases, record HP_0000093. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000093
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Proteinuria
- Open Targets ID
- HP_0000093
- Other names
- High urine protein levels, Protein in urine
- Highest stage of its drugs
- Approval, for 1 of its 58 drugs, from DailyMed and PMDA
Source Open Targets
Drugs58
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LOSARTAN POTASSIUM | CHEMBL995 | Small molecule | Approval | DailyMed and PMDA | 5 | 1 | 1 | Drugs and targets |
| DAPAGLIFLOZIN | CHEMBL429910 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| LOSARTAN | CHEMBL191 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 5 | Drugs and targets |
| PARICALCITOL | CHEMBL1200622 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| FINERENONE | CHEMBL2181927 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SPARSENTAN | CHEMBL539423 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ZIBOTENTAN | CHEMBL1628688 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ATRASENTAN | CHEMBL9194 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANDESARTAN CILEXETIL | CHEMBL1014 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 58
See all 58 drugsTargets58
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 8 | Type-1 angiotensin II receptor antagonist | Approval | https://conductscience.org/library/genes/185 | Drugs and targets |
| EDNRA | Endothelin receptor, ET-A/ET-B | 5 | Endothelin receptor ET-A antagonist; Endothelin receptor, ET-A/ET-B antagonist | Phase 3 | https://conductscience.org/library/genes/1909 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 3 | Angiotensin-converting enzyme inhibitor | Phase 3 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 3 | HMG-CoA reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 2 | Mineralocorticoid receptor antagonist | Phase 3 | https://conductscience.org/library/genes/4306 | Drugs and targets |
| VDR | Vitamin D3 receptor | 2 | Vitamin D receptor agonist | Phase 3 | https://conductscience.org/library/genes/7421 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 1 | https://conductscience.org/library/genes/775 | Drugs and targets |
1 to 10 of 58
See all 58 targetsTrials61
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03762850 | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | Phase 3 | 406 | 2024-07-03 | Immunoglobulin A Nephropathy | DAPAGLIFLOZIN, SPARSENTAN | Its record names the disease | ClinicalTrials.gov |
| NCT00296374 | Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease | Phase 2 | 353 | 2010-12-30 | Diabetes Mellitus | ATORVASTATIN, ROSUVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00568178 | An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) | Phase 3 | 306 | 2009-10-30 | Proteinuria | ENALAPRIL, LOSARTAN | Its record names the disease | ClinicalTrials.gov |
| NCT00296400 | Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease | Phase 2 | 237 | 2010-12-30 | Hyperlipidemia | ATORVASTATIN, ROSUVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT01613118 | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Phase 2 | 109 | 2021-07-27 | Focal Segmental Glomerulosclerosis | IRBESARTAN, SPARSENTAN | Its record names the disease | ClinicalTrials.gov |
| NCT03190694 | Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria | Phase 2 | 53 | 2024-06-17 | Chronic Kidney Diseases, Proteinuria | DAPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
| NCT01601236 | Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients | Phase 2 | 34 | 2017-07-24 | Diabetic Nephropathy | CORTICOTROPIN | Its record names the disease | ClinicalTrials.gov |
| NCT00324675 | Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy | Not applicable | 28 | 2011-10-21 | Type 2 Diabetes, Overt Diabetic Nephropathy | ROSIGLITAZONE | Its record names the disease | ClinicalTrials.gov |
| NCT01044771 | Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria | Not applicable | 20 | 2015-05-12 | HIV Infections, Proteinuria | RALTEGRAVIR, TENOFOVIR | Its record names the disease | ClinicalTrials.gov |
| NCT02327403 | Belatacept Conversion in Proteinuric Kidney Transplant Recipients | Phase 2 | 15 | 2022-11-09 | Proteinuria | BELATACEPT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 61
See all 61 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sparsentan vs Irbesartan: deaths from any cause | 0 of 202 | 1 of 202 | 404 | NCT03762850 | Trial comparisons |
| Sparsentan vs Irbesartan: serious adverse events | 75 of 202 | 71 of 202 | 404 | NCT03762850 | Trial comparisons |
| Dapagliflozin 10mg Tablet vs Placebo Matching Dapagliflozin Tablet: deaths from any cause | 0 of 53 | 0 of 52 | 105 | NCT03190694 | Trial comparisons |
| Dapagliflozin 10mg Tablet vs Placebo Matching Dapagliflozin Tablet: serious adverse events | 1 of 53 | 1 of 52 | 105 | NCT03190694 | Trial comparisons |
| Rosiglitazone vs Placebo: serious adverse events | 1 of 14 | 2 of 14 | 28 | NCT00324675 | Trial comparisons |
Papers from its trials73
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000093
GET https://conductscience.org/api/diseases/v1/HP_0000093/drugs?page=2